Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease
Editorial Group: Cochrane Renal Group
Published Online: 13 JUN 2012
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Palmer SC, Nand K, Dwi Nur Hidayati L, Munasinghe A, Nelson C, Khafaji MMH, Strippoli GFM. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No.: CD009904. DOI: 10.1002/14651858.CD009904.
- Publication Status: New
- Published Online: 13 JUN 2012
This is the protocol for a review and there is no abstract. The objectives are as follows:
This review aims to look at the benefits and harms of CERA compared with other epoetins (darbepoetin alfa and erythropoietin alfa or beta) or placebo/no treatment for anaemia in individuals with CKD.